NCT00517920View on ClinicalTrials.gov

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2012

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

ABT-869

0.25 mg/kg QD

Trial Locations (6)

10002

Site Reference ID/Investigator# 6265, Taipei

19107

Site Reference ID/Investigator# 7726, Philadelphia

119228

Site Reference ID/Investigator# 5235, Singapore

169610

Site Reference ID/Investigator# 5611, Singapore

M5G 2M9

Site Reference ID/Investigator# 7169, Toronto

V5Z 4E6

Site Reference ID/Investigator# 5837, Vancouver

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY